Top

Published in:

01-02-2014 | RHINOSINUSITIS (J MULLOL, SECTION EDITOR)

The Common Cold: Potential for Future Prevention or Cure

Authors: Maria Passioti, Paraskevi Maggina, Spyridon Megremis, Nikolaos G. Papadopoulos

Published in: Current Allergy and Asthma Reports | Issue 2/2014

Abstract

The common cold is the most frequent, although generally mild, human disease. Human Rhinoviruses are the prevalent causative agents, but other viruses are also implicated. Being so common, viral colds, have significant implications on public health and quality of life, but may also be life-threatening for vulnerable groups of patients. Specific diagnosis and treatment of the common cold still remain unmet needs. Molecular diagnostic techniques allow specific detection of known pathogens as well as the identification of newly emerging viruses. Although a number of medications or natural treatments have been shown to have some effect, either on the number or on the severity of common colds, no single agent is considerably effective. Virus-specific management remains in most cases a challenging potential as many factors have to be taken into account, including the diversity of the viral genomes, the heterogeneity of affected individuals, as well as the complexity of this long standing host-virus relationship.

Fokkens WJ et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;23:3. p preceding table of contents, 1–298.PubMed

Heikkinen T, Jarvinen A. The common cold. Lancet. 2003;361(9351):51–9.PubMed

Roelen CA, Koopmans PC, Notenbomer A, Groothoff JW, et al. Job satisfaction and short sickness absence due to the common cold. Work. 2011;39(3):305–13.PubMed

Kenealy T, Arroll B. Antibiotics for the common cold and acute purulent rhinitis. Cochrane Database Syst Rev. 2013;6, CD000247.PubMed

Leder K, Sinclair MI, Mitakakis TZ, Hellard ME, Forbes A. A community-based study of respiratory episodes in Melbourne, Australia. Aust N Z J Public Health. 2003;27(4):399–404.PubMed

Gruber C et al. History of respiratory infections in the first 12 yr among children from a birth cohort. Pediatr Allergy Immunol. 2008;19(6):505–12.PubMed

Ball TM et al. Influence of attendance at day care on the common cold from birth through 13 years of age. Arch Pediatr Adolesc Med. 2002;156(2):121–6.PubMed

Pitkaranta A et al. Lowered yields of virus-induced interferon production in leukocyte cultures and risk of recurrent respiratory infections in children. J Clin Virol. 1999;14(3):199–205.PubMed

Cohen S et al. Positive emotional style predicts resistance to illness after experimental exposure to rhinovirus or influenza a virus. Psychosom Med. 2006;68(6):809–15.PubMed

10.

Herlov-Nielsen H, Permin H. Common cold–risk factors, transmission and treatment. Ugeskr Laeger. 2001;163(41):5643–6.PubMed

11.

Nieman DC. Exercise, upper respiratory tract infection, and the immune system. Med Sci Sports Exerc. 1994;26(2):128–39.PubMed

12.

Makela MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, et al. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol. 1998;36(2):539–42.PubMedCentralPubMed

13.

Monto AS. Epidemiology of viral respiratory infections. Am J Med. 2002;112(Suppl 6A):4S–12S.PubMed

14.

Grief SN. Upper respiratory infections. Prim Care. 2013;40(3):757–70.PubMed

15.

Jartti T, Jartti L, Ruuskanen O, Söderlund-Venermo M. New respiratory viral infections. Curr Opin Pulm Med. 2012;18(3):271–8.PubMed

16.

Weigl JA et al. Ten years' experience with year-round active surveillance of up to 19 respiratory pathogens in children. Eur J Pediatr. 2007;166(9):957–66.PubMed

17.

Kahn J. Human bocavirus: clinical significance and implications. Curr Opin Pediatr. 2008;20(1):62–6.PubMed

18.

Gwaltney Jr JM et al. Rhinovirus infections in an industrial population. I. The occurrence of illness. N Engl J Med. 1966;275(23):1261–8.PubMed

19.

Monto AS, Johnson KM. A community study of respiratory infections in the tropics. II. The spread of six rhinovirus isolates within the community. Am J Epidemiol. 1968;88(1):55–68.PubMed

20.

Briese T et al. Global distribution of novel rhinovirus genotype. Emerg Infect Dis. 2008;14(6):944–7.PubMed

21.

Arakawa M, Okamoto-Nakagawa R, Toda S, Tsukagoshi H, Kobayashi M, Ryo A. Molecular epidemiological study of human rhinovirus species A, B and C from patients with acute respiratory illnesses in Japan. J Med Microbiol. 2012;61(3):410–9.PubMed

22.

Jefferson T, Del Mar C, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2011;7, CD006207.PubMed

23.

Gern JE et al. Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection. Am J Respir Crit Care Med. 2000;162(6):2226–31.PubMed

24.•

Jacobs SE et al. Human rhinoviruses. Clin Microbiol Rev. 2013;26(1):135–62. This review provides a summary of pathogenesis, clinical epidemiology, and laboratory features of and treatment and prevention strategies for RVs. PubMedCentralPubMed

25.

Winther B et al. Light and scanning electron microscopy of nasal biopsy material from patients with naturally acquired common colds. Acta Otolaryngol. 1984;97(3–4):309–18.PubMed

26.•

Triantafilou K, Vakakis E, Richer EA, Evans GL, Villiers JP, Triantafilou M. Human rhinovirus recognition in non-immune cells is mediated by Toll-like receptors and MDA-5, which trigger a synergetic pro-inflammatory immune response. Virulence. 2011;2(1):22–9. This article gives insight on the host's immune response mechanisms during common cold caused by rhinovirus that give rise to inflammation that defines common cold symptoms. PubMed

27.

Papadopoulos NG et al. Rhinoviruses infect the lower airways. J Infect Dis. 2000;181(6):1875–84.PubMed

28.

Lessler J et al. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291–300.PubMed

29.

Harris 2nd JM, Gwaltney Jr JM. Incubation periods of experimental rhinovirus infection and illness. Clin Infect Dis. 1996;23(6):1287–90.PubMed

30.

Gwaltney Jr JM, Hendley JO, Patrie JT. Symptom severity patterns in experimental common colds and their usefulness in timing onset of illness in natural colds. Clin Infect Dis. 2003;36(6):714–23.PubMed

31.

Iwane MK, Prill MM, Lu X, Miller EK, Edwards KM, Hall CB. Human rhinovirus species associated with hospitalizations for acute respiratory illness in young US children. J Infect Dis. 2011;204(11):1702–10.PubMed

32.

Singleton RJ, Bulkow LR, Miernyk K, DeByle C, Pruitt L, Hummel KB. Viral respiratory infections in hospitalized and community control children in Alaska. J Med Virol. 2010;82(7):1282–90.PubMed

33.

Graat JM, Schouten EG, Heijnen ML, Kok FJ, Pallast EG, de Greeff SC, et al. A prospective, community-based study on virologic assessment among elderly people with and without symptoms of acute respiratory infection. J Clin Epidemiol. 2003;56(12):1218–23.PubMed

34.

Armengol CE, Hendley JO, Winther B. Occurrence of acute otitis media during colds in children younger than four years. Pediatr Infect Dis J. 2011;30(6):518–20.PubMed

35.

Marom T, Nokso-Koivisto J, Chonmaitree T. Viral-bacterial interactions in acute otitis media. Curr Allergy Asthma Rep. 2000;12(6):551–8.

36.

Esposito S, Marchisio P, Tenconi R, Tagliaferri L, Albertario G, Patria MF, et al. Diagnosis of acute rhinosinusitis. Pediatr Allergy Immunol. 2012;23(22):17–9.PubMed

37.

Welge-Lussen A, Wolfensberger M. Olfactory disorders following upper respiratory tract infections. Adv Otorhinolaryngol. 2006;63:125–32.PubMed

38.

Papadopoulos NG. Do rhinoviruses cause pneumonia in children? Paediatr Respir Rev. 2004;5(A):S191–5.PubMed

39.

Ruuskanen O et al. Viral pneumonia. Lancet. 2011;377(9773):1264–75.PubMed

40.

Corne JM et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet. 2002;359(9309):831–4.PubMed

41.

Papadopoulos NG et al. Viruses and bacteria in acute asthma exacerbations–a GA(2) LEN-DARE systematic review. Allergy. 2011;66(4):458–68.PubMed

42.

Wark PA et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937–47.PubMedCentralPubMed

43.

Kherad O, Kaiser L, Bridevaux PO, Sarasin F, Thomas Y, Janssens JP, et al. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest. 2010;138(4):896–904.PubMed

44.

de Almeida MB, Zerbinati RM, Tateno AF, Oliveira CM, Romão RM, Rodrigues JC, et al. Rhinovirus C and respiratory exacerbations in children with cystic fibrosis. Emerg Infect Dis. 2010;16(6):996–9.PubMed

45.

Crooks BN, Taylor CE, Turner AJ, Osman HK, Abinun M, Flood TJ, et al. Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit. Bone Marrow Transplant. 2000;26(10):1097–102.PubMed

46.•

Kraft CS, Jacob JT, Sears MH, Burd EM, Caliendo AM, Marshall Lyon G. Severity of human rhinovirus infection in immunocompromised adults is similar to that of 2009 H1N1 influenza. J Clin Microbiol. 2012;50(3):1061–3. This study demonstrates that human rhinovirus infection is associated with significant morbidity and mortality in immunocompromised individuals. PubMedCentralPubMed

47.

Luinstra K, Petrich A, Castriciano S, Ackerman M, Chong S, Carruthers S, et al. Evaluation and clinical validation of an alcohol-based transport medium for preservation and inactivation of respiratory viruses. J Clin Microbiol. 2011;49(6):2138–42.PubMedCentralPubMed

48.

Landry ML, Cohen S, Ferguson D. Impact of sample type on rapid detection of influenza virus A by cytospin-enhanced immunofluorescence and membrane enzyme-linked immunosorbent assay. J Clin Microbiol. 2000;38(1):429–30.PubMedCentralPubMed

49.

Jartti T, Hedman K, Jartti L, Ruuskanen O, Allander T, Söderlund-Venermo M. Human bocavirus-the first 5 years. Rev Med Virol. 2012;22(1):46–64.PubMed

50.

Mahony JB, Petrich A, Smieja M. Molecular diagnosis of respiratory virus infections. Crit Rev Clin Lab Sci. 2011;48(5–6):217–49.PubMed

51.

Jartti T, Söderlund-Venermo M, Hedman K, Ruuskanen O, Mäkelä MJ. New molecular virus detection methods and their clinical value in lower respiratory tract infections in children. Paediatr Respir Rev. 2013;14(1):38–45.PubMed

52.

Turner RB, Fuls JL, Rodgers ND, Goldfarb HB, Lockhart LK, Aust LB. A randomized trial of the efficacy of hand disinfection for prevention of rhinovirus infection. Clin Infect Dis. 2012;54(10):1422–6.PubMed

53.•

Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis. 2011;52(1):1–7. A clinical study of a novel influenza vaccine designed to boost cross-reactive immune responses to all influenza A subtypes. PubMed

54.

Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogev R, et al. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. Vaccine. 2013;31(48):5706–12.PubMed

55.

Simancas-Racines D, Guerra CV, Hidalgo R. Vaccines for the common cold. Cochrane Database Syst Rev. 2013;6, CD002190.PubMed

56.

Fu YH, He JS, Qiao W, Jiao YY, Hua Y, Zhang Y, et al. Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice. Virol J. 2013;10:183.PubMedCentralPubMed

57.•

Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, de Haan A. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS One. 2012;7(5):e36812. Study describing a safe and effective intramuscular virosomal RSV vaccine adjuvanted with Monophosphoryl Lipid A in mice. PubMedCentralPubMed

58.•

Rigter A, Widjaja I, Versantvoort H, Coenjaerts FEJ, van Roosmalen M, Leenhouts K, et al. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS One. 2013;8(8):e71072. Study describing a safe and effective intranasal vaccine in mice and cotton rats that is based on recombinant fusion (F) protein bound to the surface of immunostimulatory bacterium. PubMedCentralPubMed

59.

Palmenberg AC et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science. 2009;324(5923):55–9.PubMed

60.•

Bochkov YA, Palmenberg AC, Lee WM, Rathe JA, Amineva SP, Sun X, et al. Molecular modeling, organ culture and reverse genetics for a newly identified human rhinovirus C. Nat Med. 2011;17(5):627–32. Study describing for the first time the propagation of two HRV-C isolates in organ culture of nasal epithelial cells, sequencing a new C15 isolate, developed the first reverse genetics system for HRV-C and predicted a unique cell attachment site for HRV-Cs. PubMedCentralPubMed

61.•

Megremis S, Demetriou P, Makrinioti H, Manoussaki AE, Papadopoulos NG. The genomic signature of human rhinoviruses A, B and C. PLoS One. 2012;7(9):e44557. Study presents for the first time the genomic signature of 111 fully sequenced HRV strains from all three groups HRV-A, HRV-B and HRV-C and propose a mechanism for the rapid changes in the HRV genomic sequence under the immune-driven pressures. PubMedCentralPubMed

62.

Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med. 2008;14(2):199–204.PubMedCentralPubMed

63.••

Niespodziana K, Napora K, Cabauatan C, Focke-Tejkl M, Keller W, Niederberger V, et al. Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections. FASEB J. 2012;26(3):1001–8. Study describes how RV escapes immunity by misdirecting the human antibody response and causes recurrent infections. PubMed

64.

Katpally U, Fu T-M, Freed DC, Casimiro DR, Smith TJ, et al. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. J Virol. 2009;83(14):7040–8.PubMedCentralPubMed

65.•

McLean GR, Walton RP, Shetty S, Peel TJ, Paktiawal N, Kebadze T, et al. Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1. Antiviral Res. 2012;95(3):193–201. Study using mouse models to investigate antibody response to RV and reveals strong cross serotype RV-specific IgG responses against the RV capsid protein VP1. PubMed

66.

Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;4:CD006602.PubMed

67.

Groothuis JR, Hoopes JM, Jessie VG. Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention. Adv Ther. 2011;28(2):91–109.PubMed

68.

Schepens B, Ibañez LI, De Baets S, Hultberg A, Bogaert P, De Bleser P. Nanobodies(R) specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J Infect Dis. 2011;204(11):1692–701.PubMed

69.••

Clementi N, De Marco D, Mancini N, Solforosi L, Moreno GJ, Gubareva LV, et al. A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. PLoS One. 2011;6(12):e28001. Study describing a human monoclonal antibody capable of neutralizing subtypes responsible of all the reported pandemics, as well as other subtypes with pandemic potential. PubMedCentralPubMed

70.••

Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333(6044):850–6. Study describing a neutralizing monoclonal antibody against both group 1 and group 2 influenza A viruses with broad specificity and neutralization potency. PubMed

71.

Kim SY, Chang YJ, Cho HM, Hwang YW, Moon YS. Non-steroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev. 2013;6, CD006362.PubMed

72.

Li S et al. Acetaminophen (paracetamol) for the common cold in adults. Cochrane Database Syst Rev. 2013;7, CD008800.PubMed

73.

Simons FE. H1-antihistamines in children. Clin Allergy Immunol. 2002;17:437–64.PubMed

74.

De Sutter AI, van Driel ML, Kumar AA, Lesslar O, Skrt A. Oral antihistamine-decongestant-analgesic combinations for the common cold. Cochrane Database Syst Rev. 2012;2:CD004976.PubMed

75.

Meltzer EO, Caballero F, Scadding G. Treatment of congestion in upper respiratory diseases. Int J Gen Med. 2010;3:69–91.PubMedCentralPubMed

76.

Fiebich BL, Collado JA, Stratz C, Valina C, Hochholzer W, Muñoz E, et al. Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways. Immunopharmacol Immunotoxicol. 2012;34(1):98–106.PubMed

77.

Albalawi ZH, Othman SS, Alfaleh K. Intranasal ipratropium bromide for the common cold. Cochrane Database Syst Rev. 2013;6, CD008231.PubMed

78.

Singh M. Heated, humidified air for the common cold. Cochrane Database Syst Rev. 2013;6, CD001728.PubMed

79.

Baartmans M et al. Steam inhalation therapy: severe scalds as an adverse side effect. Br J Gen Pract. 2012;62(600):e473–7.PubMedCentralPubMed

80.

Dicpinigaitis PV. Cough: an unmet clinical need. Br J Pharmacol. 2011;163(1):116–24.PubMed

81.

Sen EF, Verhamme KM, Felisi M, 't Jong GW, Giaquinto C, Picelli G, et al. Effects of safety warnings on prescription rates of cough and cold medicines in children below 2 years of age. Br J Clin Pharmacol. 2011;71(6):943–50.PubMed

82.

Hayward G, Thompson MJ, Perera R, Del Mar CB, Glasziou PP, Heneghan CJ. Corticosteroids for the common cold. Cochrane Database Syst Rev. 2012;8:CD008116.PubMed

83.

Barrett B et al. Echinacea for treating the common cold: a randomized trial. Ann Intern Med. 2010;153(12):769–77.PubMedCentralPubMed

84.

Singh M, Das RR. Zinc for the common cold. Cochrane Database Syst Rev. 2013;6:CD001364.PubMed

85.

Mao S, Huang S. Vitamin D supplementation and risk of respiratory tract infections: a meta-analysis of randomized controlled trials. Scand J Infect Dis. 2013;45(9):696–702.PubMed

86.

Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies. J Steroid Biochem Mol Biol. 2013;136:321–9.PubMed

87.

Bergman P, Lindh AU, Björkhem-Bergman L, Lindh JD, et al. Vitamin D and respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2013;8(6):e65835.PubMedCentralPubMed

88.•

Science M, Maguire JL, Russell ML, Smieja M, Walter SD, Loeb M. Low serum 25-hydroxyvitamin D level and risk of upper respiratory tract infection in children and adolescents. Clin Infect Dis. 2013;57(3):392–7. This study demonstrate that low serum 25(OH) D levels are associated with increased risk of laboratory-confirmed viral RTI in children in a dose depending way. PubMed

89.

Murdoch DR, Slow S, Chambers ST, Jennings LC, Stewart AW, Priest PC, et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA. 2012;308(13):1333–9.PubMed

90.

Arroll B. Common cold. Am Fam Physician. 2011;84(12):1390–1.PubMed

91.

Maggini S, Beveridge S, Suter M. A combination of high-dose vitamin C plus zinc for the common cold. J Int Med Res. 2012;40(1):28–42.PubMed

92.

Hemila H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013;1, CD000980.PubMed

93.

Linde K, Barrett B, Wölkart K, Bauer R, Melchart D. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2006;1, CD000530.PubMed

94.

Nahas R, Balla A. Complementary and alternative medicine for prevention and treatment of the common cold. Can Fam Physician. 2011;57(1):31–6.PubMedCentralPubMed

95.

Jawad M et al. Safety and efficacy profile of echinacea purpurea to prevent common cold episodes: a randomized, double-blind, Placebo-Controlled Trial. Evid Based Complement Alternat Med. 2012;2012:841315.PubMedCentralPubMed

96.

Kang EJ, Kim SY, Hwang IH, Ji YJ. The effect of probiotics on prevention of common cold: a meta-analysis of randomized controlled trial studies. Korean J Fam Med. 2013;34(1):2–10.PubMedCentralPubMed

97.

Hao Q, Lu Z, Dong BR, Huang CQ, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2011;9, CD006895.PubMed

98.

Rerksuppaphol S, Rerksuppaphol L. Randomized controlled trial of probiotics to reduce common cold in schoolchildren. Pediatr Int. 2012;54(5):682–7.PubMed

99.

Shinkai S, Toba M, Saito T, Sato I, Tsubouchi M, Taira K, et al. Immunoprotective effects of oral intake of heat-killed Lactobacillus pentosus strain b240 in elderly adults: a randomised, double-blind, placebo-controlled trial. Br J Nutr. 2013;109(10):1856–65.PubMed

100.

Marotta F et al. Is there a potential application of a fermented nutraceutical in acute respiratory illnesses? An in-vivo placebo-controlled, cross-over clinical study in different age groups of healthy subjects. J Biol Regul Homeost Agents. 2012;26(2):285–94.PubMed

101.•

Ganesan S, Faris AN, Wang Q, Nanua S, Hershenson MB, et al. Quercetin inhibits rhinovirus replication in vitro and in vivo. Antiviral Res. 2012;94(3):258–71. Study demonstrating in vivo and in vitro that quercetin decreases RV infection at multiple steps in the viral life cycle. PubMedCentralPubMed

102.

Song JH, Park KS, Kwon DH, Choi HJ. Anti-human rhinovirus 2 activity and mode of action of quercetin-7-glucoside from Lagerstroemia speciosa. J Med Food. 2013;16(4):274–9.PubMed

103.

Heinz SA, Henson DA, Austin MD, Jin F, Nieman DC. Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial. Pharmacol Res. 2010;62(3):237–42.PubMed

104.•

Riede L, Grube B, Gruenwald J. Larch arabinogalactan effects on reducing incidence of upper respiratory infections. Curr Med Res Opin. 2013;29(3):251–8. A clinical trial demonstrating that larch arabinogalactan increase the body’s potential to defend against common cold infection. PubMed

105.

Leibbrandt A, Meier C, König-Schuster M, Weinmüllner R, Kalthoff D, Pflugfelder B, et al. Iota-carrageenan is a potent inhibitor of influenza A virus infection. PLoS One. 2010;5(12):e14320.PubMedCentralPubMed

106.

Grassauer A, Meier C, Pretsch A, Prieschl-Grassauer E, Unger H. Iota-carrageenan is a potent inhibitor of rhinovirus infection. Virol J. 2008;5:107.PubMedCentralPubMed

107.

Eccles R, Meier C, Prieschl-Grassauer E. Efficacy and safety of an antiviral iota-carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respir Res. 2010;11:108.PubMedCentralPubMed

108.

Fazekas T, Eickhoff P, Pruckner N, Vollnhofer G, Fischmeister G, Diakos C, et al. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold. BMC Complement Altern Med. 2012;12:147.PubMedCentralPubMed

109.

Auinger A, Riede L, Bothe G, Busch R, Gruenwald J. Yeast (1,3)-(1,6)-beta-glucan helps to maintain the body's defence against pathogens: a double-blind, randomized, placebo-controlled, multicentric study in healthy subjects. Eur J Nutr. 2013;52(8):1913–8.PubMedCentralPubMed

110.

Graubaum H-J, Busch R, Stier H, Gruenwald J. A doubleblind, randomized, placebo-controlled nutritional study using an insoluble yeast beta-glucan to improve the immune defense system. Food Nut Sci. 2012;3:738–46.

111.

Yates PJ et al. Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza. Antimicrob Agents Chemother. 2013;57(4):1677–84.PubMedCentralPubMed

112.

Michiels B et al. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One. 2013;8(4):e60348.PubMedCentralPubMed

113.

Wang K et al. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst Rev. 2012;4:CD002744.PubMed

114.

Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev. 2010;23(1):74–98.PubMedCentralPubMed

115.•

Olszewska W, Ispas G, Schnoeller C, Sawant D, Van de Casteele T, Nauwelaers D, et al. Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J. 2011;38(2):401–8. This study describes a new antiviral agent that reduces RSV replication and inhibits lung inflammation in mice. PubMed

116.

Sun Z et al. Respiratory syncytial virus entry inhibitors targeting the F protein. Virus. 2013;5(1):211–25.

117.

Maugeri C et al. New anti-viral drugs for the treatment of the common cold. Bioorg Med Chem. 2008;16(6):3091–107.PubMed

118.

Patick AK. Rhinovirus chemotherapy. Antiviral Res. 2006;71(2–3):391–6.PubMed

119.•

Rollinger JM, Schmidtke M. The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. Med Res Rev. 2011;31(1):42–92. This is an extensive review of existing knowledge about mechanisms of anti-RV agents from synthetic and natural origin, and future potentials. PubMed

120.

Gwaltney Jr JM et al. Combined antiviral-antimediator treatment for the common cold. J Infect Dis. 2002;186(2):147–54.PubMed

121.

Gao L et al. A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine. 2010;28(28):4445–51.PubMed

122.••

Campbell-Harding G, Sawkins H, Bedke N, Holgate ST, Davies DE, Andrews AL, et al. The innate antiviral response upregulates IL-13 receptor alpha2 in bronchial fibroblasts. J Allergy Clin Immunol. 2013;131(3):849–55. This study enlightens the role of IFN-beta and IL-13 in innate antiviral immune response. PubMed

123.

Yamaya M et al. Levofloxacin inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Antimicrob Agents Chemother. 2012;56(8):4052–61.PubMedCentralPubMed

124.

Koutsoubari I et al. Effect of clarithromycin on acute asthma exacerbations in children: an open randomized study. Pediatr Allergy Immunol. 2012;23(4):385–90.PubMed

125.

Min JY, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators Inflamm. 2012;2012:649570.PubMedCentralPubMed

126.

Jurgeit A et al. Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects. PLoS Pathog. 2012;8(10):e1002976.PubMedCentralPubMed

127.

Yoshihara S et al. Inhibition of common cold-induced aggravation of childhood asthma by leukotriene receptor antagonists. Allergol Int. 2012;61(3):405–10.PubMed

128.

Kozer E et al. RCT of montelukast as prophylaxis for upper respiratory tract infections in children. Pediatrics. 2012;129(2):e285–90.PubMed

129.

Kloepfer KM. Effects of montelukast on patients with asthma after experimental inoculation with human rhinovirus 16. Ann Allergy Asthma Immunol. 2011;106(3):252–7.PubMedCentralPubMed

130.

Yamaya M et al. Inhibitory effects of tiotropium on rhinovirus infection in human airway epithelial cells. Eur Respir J. 2012;40(1):122–32.PubMed

131.

Gern JE et al. Inhibition of rhinovirus replication in vitro and in vivo by acid-buffered saline. J Infect Dis. 2007;195(8):1137–43.PubMed

132.

Van Blerkom LM. Role of viruses in human evolution. Am J Phys Anthropol. 2003;37:14–46.PubMed

Title: The Common Cold: Potential for Future Prevention or Cure
Authors: Maria Passioti
Paraskevi Maggina
Spyridon Megremis
Nikolaos G. Papadopoulos
Publication date: 01-02-2014
Publisher: Springer US
Published in: Current Allergy and Asthma Reports / Issue 2/2014
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-013-0413-5

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The Common Cold: Potential for Future Prevention or Cure

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Targeting the Molecular and Cellular Interactions of the Bone Marrow Niche in Immunologic Disease

Genetic Contributors to Otitis Media: Agnostic Discovery Approaches

Occupational Skin Allergies: Testing and Treatment (The Case of Occupational Allergic Contact Dermatitis)

Indications for Surgery in Refractory Rhinitis

MicroRNA in Chronic Rhinosinusitis and Allergic Rhinitis

Preventing Progression of Allergic Rhinitis to Asthma